ATE309980T1 - Zubereitungen zur verwendung als therapeutische und nachweismittel - Google Patents

Zubereitungen zur verwendung als therapeutische und nachweismittel

Info

Publication number
ATE309980T1
ATE309980T1 AT97949046T AT97949046T ATE309980T1 AT E309980 T1 ATE309980 T1 AT E309980T1 AT 97949046 T AT97949046 T AT 97949046T AT 97949046 T AT97949046 T AT 97949046T AT E309980 T1 ATE309980 T1 AT E309980T1
Authority
AT
Austria
Prior art keywords
thrag
tyrx
therapeutic
preparations
drugs
Prior art date
Application number
AT97949046T
Other languages
English (en)
Inventor
Patrick Anthony Riley
Andrew Photiou
Tariq Hussain Khan
Helen Mary Isted Osborn
Original Assignee
Patrick Anthony Riley
Andrew Photiou
Tariq Hussain Khan
Helen Mary Isted Osborn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick Anthony Riley, Andrew Photiou, Tariq Hussain Khan, Helen Mary Isted Osborn filed Critical Patrick Anthony Riley
Application granted granted Critical
Publication of ATE309980T1 publication Critical patent/ATE309980T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43Y being a hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02Monothiocarbamic acids; Derivatives thereof
    • C07C333/04Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97949046T 1996-12-13 1997-12-12 Zubereitungen zur verwendung als therapeutische und nachweismittel ATE309980T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9625895.9A GB9625895D0 (en) 1996-12-13 1996-12-13 Novel compound useful as therapeutic agents and assay reagents
PCT/GB1997/003433 WO1998025886A1 (en) 1996-12-13 1997-12-12 Novel compounds useful as therapeutic agents and assay reagents

Publications (1)

Publication Number Publication Date
ATE309980T1 true ATE309980T1 (de) 2005-12-15

Family

ID=10804381

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97949046T ATE309980T1 (de) 1996-12-13 1997-12-12 Zubereitungen zur verwendung als therapeutische und nachweismittel

Country Status (7)

Country Link
US (1) US6573284B1 (de)
EP (1) EP0944583B1 (de)
AT (1) ATE309980T1 (de)
AU (1) AU748957B2 (de)
DE (1) DE69734670T2 (de)
GB (1) GB9625895D0 (de)
WO (1) WO1998025886A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US7183319B2 (en) * 2000-07-26 2007-02-27 Patrick Anthony Riley Phenylethylamine derivatives and their use in the treatment of melanoma
BR0114059A (pt) * 2000-09-21 2003-07-01 Pfizer Prod Inc Derivados de resorcinol
CN1761485B (zh) * 2003-03-20 2010-04-28 日本化药株式会社 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
JP4820758B2 (ja) 2004-09-22 2011-11-24 日本化薬株式会社 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
RU2447095C2 (ru) * 2006-05-18 2012-04-10 Ниппон Каяку Кабусики Кайся Высокомолекулярный конъюгат подофиллотоксинов
JP5548364B2 (ja) * 2006-10-03 2014-07-16 日本化薬株式会社 レゾルシノール誘導体の高分子結合体
MX337408B (es) 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
JP5349318B2 (ja) 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
CN101977631A (zh) * 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
MX2010011032A (es) 2008-04-11 2011-03-01 Cytotech Labs Llc Star Metodos y uso de induccion de apoptosis en celulas cancerigenas.
JP5366940B2 (ja) * 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
JP5544357B2 (ja) 2009-05-15 2014-07-09 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
SG10202010355PA (en) * 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
KR20140024833A (ko) 2010-11-17 2014-03-03 니폰 가야꾸 가부시끼가이샤 신규한 시티딘계 대사길항제의 고분자 유도체
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
EP2720680B1 (de) 2011-06-17 2020-02-12 Berg LLC Inhalbierbare pharmazeutische zusammensetzungen
CN103874722B (zh) 2011-09-11 2016-06-29 日本化药株式会社 嵌段共聚物的制造方法
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
AU2015243537B2 (en) 2014-04-08 2020-10-22 The Methodist Hospital INOS-inhibitory compositions and their use as breast cancer therapeutics
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US12576166B2 (en) 2020-07-27 2026-03-17 Board Of Regents, The University Of Texas System Contrast agents for detection of enzyme activities based on melanin synthesis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543630A1 (de) * 1966-12-23 1969-07-31 Bayer Ag Verfahren zur Herstellung von tert. Butyloxycarbonylderivaten von Aminosaeuren
CH547799A (de) 1970-10-30 1974-04-11 Hoffmann La Roche Verfahren zur herstellung von indolinderivaten.
US3801624A (en) * 1970-12-09 1974-04-02 Aldrich Chem Co Inc Di-substituted beta-phenethylcarbamic acid esters
IT1048122B (it) * 1973-05-23 1980-11-20 Simes Carbammati di ergoline
DE2448257A1 (de) * 1974-10-10 1976-04-22 Troponwerke Dinklage & Co Cumarinabkoemmlinge, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4115539A (en) * 1976-05-17 1978-09-19 Union Carbide Corporation Analytical or clinical derivatives, tagged derivatives and methods of analysis using such derivatives
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
IL102645A (en) * 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
FR2699532B1 (fr) * 1992-12-18 1995-02-24 Oreal Nouveaux composés indolines, compositions tinctoriales à base de ces composés et procédé de teinture des fibres kératiniques.
JPH0782280A (ja) * 1993-06-30 1995-03-28 Kanebo Ltd 新規なプロドラッグおよびその製造方法
EP0731106B1 (de) * 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin-derivate
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
CA2155448A1 (en) * 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase

Also Published As

Publication number Publication date
AU7846998A (en) 1998-07-03
DE69734670D1 (de) 2005-12-22
US6573284B1 (en) 2003-06-03
EP0944583B1 (de) 2005-11-16
DE69734670T2 (de) 2006-06-29
EP0944583A1 (de) 1999-09-29
GB9625895D0 (en) 1997-01-29
WO1998025886A1 (en) 1998-06-18
AU748957B2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
ATE309980T1 (de) Zubereitungen zur verwendung als therapeutische und nachweismittel
BG106771A (en) Heterocyclic substituted pyrazolones
BR1101081A (pt) Composto e composição farmacêutica
YU40701A (sh) Piperidini kao modulatori ccr5
DE69329240D1 (de) 17-ether und thioether von 4-aza-steroiden
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
PT966465E (pt) Inibidores do enzima imfdh
GC0000221A (en) Pyrimidinone compounds, processes for their preparation, intermediates useful in their preparation, and pharmaceutical compositions containing them
TR199901578T2 (xx) Klaritromisin form 0 kristali
CA2350073A1 (en) Ccr5 modulators
DE69329856D1 (de) Ester derivate von 4-aza-steroiden
DE69432035D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
PT1206473E (pt) Pirrolocarbazoles e isoindolonas fundidos isomericos
AU1973997A (en) Pentafluorobenzenesulfonamides and analogs
DE68928667D1 (de) Peptide als arzneimittel
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
DE60101372D1 (de) Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
TR200202310T2 (tr) Östrojen agonist/antagonist metabolitleri
GB8622330D0 (en) 4-substituted 6-alkylidenandrostene-3,17-dione derivatives
TR199800521T1 (xx) Se�imli beta3 adrenerjik agonistler.
ES2145021T3 (es) Derivados de 1-bifenil-piridona, su preparacion y su uso como antagonistas de la angiotensina ii.
ATE323495T1 (de) Steroid-3-o-sulfamat-derivate als estronsulfatase-hemmer
ATE451107T1 (de) 3-o-sulfamatsteroidderivate als hemmer von estronsulfatase
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
Dolence et al. Solid-phase synthesis of a radiolabeled, biotinylated, and farnesylated Ca1a2X peptide substrate for Ras-and a-mating factor converting enzyme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties